Patenting is an essential activity that, if necessary, is managed by external patent attorneys. The main questions that arise here are whether the invention can be granted as material property of the research, whether it can be granted as copyright, whether it is capable of being patentable and enforceable, and whether the invention has already been made public. There is no solid way to manage this process. Wiesendanger said: “It can happen at any time – and that decision is up to the relevant licensor. But we must be careful; This is expensive and represents an ongoing commitment. Some universities patent everything, but we are under pressure not to. Normally, we sign licenses before we have the patents and we often start negotiating before we even file them. Often, we`ll take care of the ultimate licensees to cover the registration fee in exchange for a six-month option for the technology. This can be very attractive, as this six-month period often represents a very significant competitive advantage. Stanford, however, is still in the lead.
According to the 2002 AutM Licensing survey, Stanford received $50.2 million in adjusted gross license revenue for fiscal year 2002. Even in a challenging economic environment, this amount was the second highest in OTL`s history, including an unexpected $5.8 million in one-time royalties, with 42 of OTL`s 442 revenue-generating technologies producing more than $100,000 per year (see Box 1 for an overview of the economic impact of Stanford`s OTL). Since 2002, things have kept even better: in 2005, the OTL received $384 million on behalf of the university.3 2.9 PatentCondria means any sublicense of a licensed patent issued by GOOGLE to a third party to enable that third party to manufacture, manufacture, use, sell, sell and import its own licensed products, without GOOGLE offering products or services. Where State aid has been granted, this Agreement shall be subject to all the conditions set out in Sections 200 to 204 of Title 35 United States Code, including the obligation for licensed products sold or produced in the United States to produce primarily in the United States, and licensee undertakes to take all appropriate measures as licensee: so that STANFORD can fulfill its commitment under this obligation. with respect to licensed patents. Dari Shalon, who now runs Shalon Ventures (an early-stage life-science-VC) with his brother, served his experience with Stanford`s OTL well. A former PhD student at the university, he authorized his own invention by the OTL to launch Synteni, sold three years later for $100 million to Incyte Genomics. According to Shalon, “the technology that was eventually granted to Synteni was developed by me and Professor Patrick Brown [a painting technique that became the basis of MICROARRAY DNA technology].” Although the OTL widely disseminated the invention, no company showed serious interest, which led Shalon to set up his own company in 1995 to develop the technology. “I had done an MBA at M.I.T.,” he explained, “and then I chose Stanford as an interesting entrepreneurial university. My research project was deliberately chosen for commercial application. Shalon recalled that as a student, in a torn t-shirt and jeans, he would walk around the OTL and ask if he could submit a disclosure: “I had a series of unsuccessful efforts where the technology didn`t work, but the OTL guys encouraged me to go back to the lab and keep trying.
After all, I developed it from commercial feasibility, and I went ed on and filed it. At that time, he recalls, he was trying to get serious: “I turned into a businessman, with business cards and a suit, and I told myself that I was going to enter directly into the commercial sphere. What I didn`t understand were Stanford`s own fiduciary duties to its agents. .